PL2460820T3 - Immunogenne kompozycje PCV2 stosowane w zapobieganiu infekcjom PCV2 - Google Patents

Immunogenne kompozycje PCV2 stosowane w zapobieganiu infekcjom PCV2

Info

Publication number
PL2460820T3
PL2460820T3 PL12155382T PL12155382T PL2460820T3 PL 2460820 T3 PL2460820 T3 PL 2460820T3 PL 12155382 T PL12155382 T PL 12155382T PL 12155382 T PL12155382 T PL 12155382T PL 2460820 T3 PL2460820 T3 PL 2460820T3
Authority
PL
Poland
Prior art keywords
compositions
producing
methods
pcv2 immunogenic
pcv2
Prior art date
Application number
PL12155382T
Other languages
English (en)
Inventor
Mark Eichmeyer
Greg Nitzel
Merrill Schaeffer
Original Assignee
Boehringer Ingelheim Animal Health USA Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2460820(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/034,797 external-priority patent/US7833707B2/en
Application filed by Boehringer Ingelheim Animal Health USA Inc. filed Critical Boehringer Ingelheim Animal Health USA Inc.
Priority claimed from US11/319,975 external-priority patent/US7700285B1/en
Publication of PL2460820T3 publication Critical patent/PL2460820T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14161—Methods of inactivation or attenuation
    • C12N2710/14163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C12N2750/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
PL12155382T 2004-12-30 2005-12-29 Immunogenne kompozycje PCV2 stosowane w zapobieganiu infekcjom PCV2 PL2460820T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US64051004P 2004-12-30 2004-12-30
US11/034,797 US7833707B2 (en) 2004-12-30 2005-01-13 Methods of overexpression and recovery of porcine circovirus type 2 ORF2
EP12155382.0A EP2460820B8 (en) 2004-12-30 2005-12-29 Pcv2 immunogenic compositions and methods of producing such compositions
PCT/US2005/047596 WO2006072065A2 (en) 2004-12-30 2005-12-29 Pcv2 immunogenic compositions and methods of producing such compositions
EP05856068.1A EP1833992B1 (en) 2004-12-30 2005-12-29 Pcv2 immunogenic compositions and methods of producing such compositions
US11/319,975 US7700285B1 (en) 2005-12-29 2005-12-29 PCV2 immunogenic compositions and methods of producing such compositions

Publications (1)

Publication Number Publication Date
PL2460820T3 true PL2460820T3 (pl) 2019-09-30

Family

ID=46000496

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12155382T PL2460820T3 (pl) 2004-12-30 2005-12-29 Immunogenne kompozycje PCV2 stosowane w zapobieganiu infekcjom PCV2
PL12155378T PL2460817T3 (pl) 2004-12-30 2005-12-29 Immunogenne kompozycje PCV2 stosowane w zapobieganiu infekcjom PCV2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12155378T PL2460817T3 (pl) 2004-12-30 2005-12-29 Immunogenne kompozycje PCV2 stosowane w zapobieganiu infekcjom PCV2

Country Status (11)

Country Link
EP (4) EP2460818A3 (pl)
CN (2) CN102660578B (pl)
DK (2) DK2281829T3 (pl)
ES (4) ES2733428T3 (pl)
HR (1) HRP20150568T1 (pl)
HU (3) HUE033621T2 (pl)
PH (1) PH12014500696A1 (pl)
PL (2) PL2460820T3 (pl)
PT (3) PT2460820T (pl)
RU (1) RU2620968C9 (pl)
SI (2) SI2281829T1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2460820T (pt) 2004-12-30 2019-07-16 Boehringer Ingelheim Animal Health Usa Inc Composições imunogénicas de pcv2 e métodos de produção de tais composições
CN105026419B (zh) 2013-03-01 2021-08-24 勃林格殷格翰动物保健美国有限公司 疫苗组合物定量
WO2015026912A1 (en) * 2013-08-23 2015-02-26 Boehringer Ingelheim Vetmedica, Inc. Porcine circovirus type 2 (pcv2) subunit vaccine
CN104623653B (zh) * 2013-11-08 2017-08-01 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法
CN104873966B (zh) * 2015-04-20 2019-12-20 浙江海隆生物科技有限公司 一种猪圆环病毒2型病毒样颗粒纯化及其疫苗制备方法
CA3042584A1 (en) 2016-11-03 2018-05-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
EP3672629A1 (en) * 2018-03-26 2020-07-01 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
MX2021012051A (es) 2019-04-04 2022-01-18 Boehringer Ingelheim Animal Health Usa Inc Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US319975A (en) 1885-06-16 Teeeitoey
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3479705A (en) 1966-12-15 1969-11-25 Miami Brick & Stone Inc Of Mia Molding apparatus
EP0610250B2 (en) 1991-10-14 2008-10-29 Intervet International BV Porcine reproductive respiratory syndrome (prrs) vaccine and diagnostic
ES2152304T3 (es) 1993-02-08 2001-02-01 Bayer Ag Procedimiento para el crecimiento del virus del sindrome reproductivo y respiratorio porcino y su uso en vacunas.
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2769322B1 (fr) * 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
ES2289796T3 (es) 1997-12-11 2008-02-01 University Of Saskatchewan Virus del sindrome del desmedro post-destete procedente de cerdos.
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
CA2410229A1 (en) * 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
DK1651265T3 (da) * 2003-07-24 2008-08-18 Merial Ltd Vaccineformuleringer der omfatter en olie-i-vand-emulsion
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
PT2460820T (pt) 2004-12-30 2019-07-16 Boehringer Ingelheim Animal Health Usa Inc Composições imunogénicas de pcv2 e métodos de produção de tais composições
JP5106398B2 (ja) 2005-09-09 2012-12-26 インターベツト・インターナシヨナル・ベー・ベー Ｐｃｖ−２ワクチン
PT2481420T (pt) 2006-12-15 2019-05-31 Boehringer Ingelheim Animal Health Usa Inc Vacina para porcos anti-pcv2 de dose única

Also Published As

Publication number Publication date
EP2460820B8 (en) 2019-06-19
CN102660578B (zh) 2016-12-14
SI2281829T1 (sl) 2015-03-31
ES2538499T3 (es) 2015-06-22
EP2460819A2 (en) 2012-06-06
CN102660578A (zh) 2012-09-12
RU2620968C9 (ru) 2017-08-08
DK2281829T3 (da) 2015-02-23
EP2460820B1 (en) 2019-04-10
EP2460819A3 (en) 2013-01-09
ES2733428T3 (es) 2019-11-29
PH12014500696B1 (en) 2016-01-18
EP2460818A3 (en) 2013-01-09
PH12014500696A1 (en) 2016-01-18
EP2460821A3 (en) 2014-12-10
ES2629679T3 (es) 2017-08-14
EP2460820A2 (en) 2012-06-06
DK1833992T3 (da) 2015-06-08
HUE025537T2 (en) 2016-05-30
EP2460821A2 (en) 2012-06-06
EP2460818A2 (en) 2012-06-06
EP2460820A3 (en) 2013-01-09
CN103285387B (zh) 2017-07-25
PL2460817T3 (pl) 2017-09-29
HUE046045T2 (hu) 2020-01-28
PT2460817T (pt) 2017-07-03
RU2620968C2 (ru) 2017-05-30
SI1833992T1 (sl) 2015-06-30
ES2532861T3 (es) 2015-04-01
RU2011121850A (ru) 2012-12-10
HRP20150568T1 (hr) 2015-08-28
PT2281829E (pt) 2015-02-18
CN103285387A (zh) 2013-09-11
PT2460820T (pt) 2019-07-16
HUE033621T2 (en) 2017-12-28
RU2011132502A (ru) 2013-02-10

Similar Documents

Publication Publication Date Title
ZA200706158B (en) PCV2 immunogenic compositions and methods of producing such compositions
ZA200804957B (en) Multivalent PCV2 immunogenic compositions and methods of producing such compositions
IL190885A0 (en) Immunogenic compositions and methods of use
EP1744825A4 (en) COLLOIDAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF
IL181543A0 (en) Dendrimer based compositions and methods of using the same
IL185924A0 (en) Tigecycline compositions and methods of preparation
IL189972A0 (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
EP1786265A4 (en) NEW COMPOSITIONS AND PROCESSING METHODS
EP2041323A4 (en) VIRUSOMES, MANUFACTURING PROCESSES AND IMMUNOGENIC COMPOSITIONS
PL2460820T3 (pl) Immunogenne kompozycje PCV2 stosowane w zapobieganiu infekcjom PCV2
EP1824990A4 (en) METHOD FOR PRODUCING INFLUENZA VACCINE COMPOSITIONS
EP1773386A4 (en) VACCINE COMPOSITIONS AND CORRESPONDING METHODS
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
EP1928252A4 (en) PIGGY COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
EP1961430A4 (en) BONE COMPATIBLE IMPLANT AND METHOD OF MANUFACTURING THEREOF
GB0504657D0 (en) Compositions and methods of treatment
AU2004906753A0 (en) Methods and Preparation and Uses of Xanthorrhoeaceae Compositions
AU2005904259A0 (en) Compositions and methods of treatment
AU2005903854A0 (en) Compositions and methods of treatment
AU2005906585A0 (en) Methods and Preparation of Uses of Xanthorrhoeaceae Compositions
AU2004900511A0 (en) Compositions and Methods of Treatment
AU2004904405A0 (en) Compositions and Methods of Treatment
SI1725610T1 (sl) Biocidni sestavki in postopki njihove izdelave
SI1858488T2 (sl) Kompozicije tigeciklina in metode za pripravo